Clinical trial
A Prospective and Exploratory Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
NCT07692529 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective and Exploratory Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
- Lead sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- August 30, 2026
- Completion date
- February 26, 2028
- Enrollment
- 10 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
large granular lymphocyte leukemia, t-lgl leukemia